Share Name Share Symbol Market Type Share ISIN Share Description
Hvivo Plc LSE:HVO London Ordinary Share GB00B6ZM0X53 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 14.75 14.50 15.00 14.75 14.75 14.75 0.00 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 11.0 -18.9 -21.3 - 12

hVIVO plc Director's Dealings

03/10/2019 9:51am

UK Regulatory (RNS & others)


Hvivo (LSE:HVO)
Historical Stock Chart

2 Months : From Sep 2019 to Nov 2019

Click Here for more Hvivo Charts.

TIDMHVO

RNS Number : 6606O

hVIVO plc

03 October 2019

hVIVO plc

("hVIVO" or the "Company")

Director's Dealings

London, UK, 3 October 2019: hVIVO plc (AIM: HVO), an industry leading clinical development services business pioneering human disease models based upon viral and allergen challenge, announces that, application has been made to AIM for the admission of 25,349 new ordinary shares of 5.0p each in the Company (the "New Ordinary Shares").

The New Ordinary Shares have been allotted pursuant to the purchase by Jim Winschel (Non-Executive Director) of new ordinary shares, under the terms of his letter of appointment as set out in the Company's announcement of 4 November 2014 which stated that Mr Winschel had entered into a binding commitment to purchase GBP4,000 of hVIVO plc New Ordinary Shares per quarter.

The New Ordinary Shares represent Mr Winschel's investment for the quarter ended September 2019. On 3 October 2019, Mr Winschel invested in an additional 25,349 ordinary shares, at a price of 15.78 pence per share.

Following admission of the New Ordinary Shares to trading on AIM, the total number of Ordinary Shares with voting rights in issue will be 83,235,251 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

Admission of the New Ordinary Shares ("Admission"), which will rank pari passu in all respects with the Company's existing shares in issue, is expected to occur on 9 October 2019. Following Admission, Mr Winschel will be interested in a total of 154,548 ordinary shares of 5.0p in the Company, representing 0.1% of the Company's issued share capital.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail:

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
 1    Details of the persons discharging managerial responsibilities/persons 
       closely associated 
 a)   Name                         Jim Winschel 
     ---------------------------  -------------------------------------------- 
 2    Reason for the notification 
     ------------------------------------------------------------------------- 
 a)   Position/                    Non-Executive Director 
       status 
     ---------------------------  -------------------------------------------- 
 b)   Initial notification/        Initial Notification 
       Amendment 
     ---------------------------  -------------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ------------------------------------------------------------------------- 
 a)   Name                         hVIVO plc 
     ---------------------------  -------------------------------------------- 
 b)   Legal Entity                 N/A 
       Identifier 
     ---------------------------  -------------------------------------------- 
 4    Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ------------------------------------------------------------------------- 
 a)   Description                  Ordinary shares of 5 pence each 
       of the financial 
       instrument, 
       type of instrument           GB00B6ZM0X53 
 
       Identification 
       code 
     ---------------------------  -------------------------------------------- 
 b)   Nature of                    Acquisition of ordinary shares 
       the transaction 
     ---------------------------  -------------------------------------------- 
 c)   Currency                     GBP 
     ---------------------------  -------------------------------------------- 
 d)   Price(s) and                      Director        Price (p)   Volume 
       volume(s)                        Jim Winschel    15.78       25,349 
                                                       ----------  ------- 
     --------------------------- 
 
 e)   Aggregated 
       information 
       - Aggregated 
        volume 
       - Price                      25,349 
       - Aggregated                  15.78 
        total 
                                     GBP4,000.07 
     ---------------------------  -------------------------------------------- 
 f)   Date of the                  3 October 2019 
       transaction 
     ---------------------------  -------------------------------------------- 
 g)   Place of the                 London Stock Exchange, AIM 
       transaction 
     ---------------------------  -------------------------------------------- 
 

For further information please contact:

 
 Anesh Patel (Interim Finance Director & Company Secretary)    +44 207 756 1300 
 Fleur Wood (EVP, Investor Relations & Communications) 
 Numis Securities Limited                                       +44 207 260 1000 
 Freddie Barnfield / Huw Jeremy (Nominated Adviser) 
 James Black (Corporate Broking) 
 
 FTI Consulting 
 Simon Conway / Victoria Foster Mitchell                       +44 203 727 100 
 

Notes to Editors:

hVIVO is an industry leading clinical development services business supporting product development for customers developing antivirals, vaccines and respiratory therapeutics. Leveraging human disease models in human rhinovirus (HRV), RSV, Influenza (Flu) Asthma and chronic obstructive pulmonary disease (COPD), the hVIVO platform illuminates the entire disease cycle in people from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted 56 clinical studies and inoculated over 2900 volunteers.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHUGGUAUUPBURW

(END) Dow Jones Newswires

October 03, 2019 04:51 ET (08:51 GMT)

1 Year Hvivo Chart

1 Year Hvivo Chart

1 Month Hvivo Chart

1 Month Hvivo Chart
Your Recent History
LSE
HVO
Hvivo
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20191120 19:39:41